$15M Investment Helps Secure Funding for Phase 2 Trial of T3D-959 for Alzheimer’s

$15M Investment Helps Secure Funding for Phase 2 Trial of T3D-959 for Alzheimer’s
T3D Therapeutics has secured the needed funding to move forward with its Phase 2 trial testing T3D-959 as a potential treatment for people with mild-to-moderate Alzheimer’s disease. The total funding includes $15 million from an investor, in addition to a $9 million award from the National Institute on Aging (NIA), part of the National Institutes of Health. Enrollment is planned to begin during the first quarter of 2020. Some researchers believe that Alzheimer’s is a metabolic disease caused by age-related dysfunctions, sometimes called type 3 diabetes. T3D-959 is an investigative oral therapy that activates two proteins — called PPAR delta and PPAR gamma — involved in regulating blood sugar and triglyceride (fat) levels. PPAR activation regulates these metabolic parameters by boosting insulin sensitivity, an approach used to overcome insulin resistance in diabetes therapy. Researchers think that T3D-959 may improve the glucose and lipid metabolism dysfunctions seen in Alzheimer’s disease. "We believe T3D-959 has the potential to be Alzheimer's disease remedial, to either
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *